Indications › Metabolic syndrome

GLP‑1 drugs in metabolic syndrome

Which incretin agents are being studied in metabolic syndrome, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file

14

Active

8

Results scheduled

1

Molecules studied

4

Sponsors

13

No GLP‑1 or incretin drug is FDA-approved for metabolic syndrome. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.

No GLP-1 or incretin drug is approved for metabolic syndrome, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 13 of the 14 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 1 still in early phases. 13 distinct sponsors are involved.

Molecules studied in this indication

exenatide · liraglutide · semaglutide · tirzepatide

Results due in this indication

Trials on file

All 14 incretin trials recorded in this indication, active first.